Par Drugs & Chemicals Ltd
Incorporated in 1982, Par Drugs & Chemicals Ltd manufactures APIs and Fine Chemicals[1]
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
| Free Cash Flow |
| CFO/OP |
Ratios
Figures in Rs. Crores
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
| Total Installed Capacity MTPA ・Standalone data |
|
|||||||
| Capacity Utilization % ・Standalone data |
||||||||
| Total Permanent Employees Count ・Standalone data |
||||||||
| Utilized Production / Sales Quantity MTPA ・Standalone data |
||||||||
| Export Presence (Number of Countries) Count ・Standalone data |
||||||||
| Solar Power Generation kWh ・Standalone data |
||||||||
| Total Number of Products Manufactured Count ・Standalone data |
||||||||
| Number of Customers Count ・Standalone data |
||||||||
Documents
Announcements
-
Trading Window
26 March 2026 - Trading window closed Apr 1, 2026 until 48 hours after Q4/FY Mar 31, 2026 results; applies to designated insiders.
-
Action(s) taken or orders passed
26 March 2026 - Document contains only digital signatures and timestamps dated 2026-03-26.
-
Copy of Newspaper Publication
11 February 2026 - Standalone unaudited results for quarter/nine months ended 31‑Dec‑2025: Revenue Rs2,933.95L; Q PBT Rs644.20L; PAT Rs479.72L
-
Outcome of Board Meeting
10 February 2026 - Q3/9M FY26 standalone: Revenue Rs3,066.50L (Qtr), 9M Rs8,768.71L; 9M profit Rs1,225.49L
-
Outcome of Board Meeting
10 February 2026 - Approved unaudited Q3 and nine-month results: Q3 profit Rs.479.72L, YTD profit Rs.1,225.49L, LR unmodified.
Annual reports
Concalls
-
Jun 2023TranscriptAI SummaryPPT
-
Jun 2023TranscriptAI SummaryPPT
-
Mar 2023TranscriptAI SummaryPPT
-
Mar 2023TranscriptAI SummaryPPT
-
Feb 2023TranscriptAI SummaryPPT
-
Nov 2022TranscriptAI SummaryPPT
-
Nov 2022TranscriptAI SummaryPPT
-
Aug 2022TranscriptAI SummaryPPT
-
May 2022TranscriptAI SummaryPPT
-
Feb 2022TranscriptAI SummaryPPT
-
Dec 2021TranscriptAI SummaryPPT
-
Nov 2021TranscriptAI SummaryPPT
-
Jun 2021TranscriptAI SummaryPPT
-
Nov 2020TranscriptAI SummaryPPT
-
Nov 2020TranscriptAI SummaryPPT
-
Jun 2020TranscriptAI SummaryPPT
-
Sep 2019TranscriptAI SummaryPPT
Business Overview:[1]
PACL manufactures Active Pharma Ingredients for domestic and exports markets, they have a portfolio of 15 APIs and 10 Fine Chemicals. It produces the entire range of products in the Antacid Molecules segment